Sequana Medical said the first implantation of the alfapump in the U.S. at Mount Sinai Hospital received FDA approval for the treatment of recurrent or refractory ascites due to liver cirrhosis.
Sequana Medical said the company now has five medical centers using its alfapump, the first FDA-approved active implantable medical device to treat liver ascites due to cirrhosis. The new ...
Ghent, Belgium, 26 February 2026 - Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...
Consistent and permanent abstinence from alcohol can lead to the regression of existing liver-related complications, even in ...
Evaluation of the appropriateness of a potential candidate for OLT is a complex process and involves a multidisciplinary approach. The evaluation begins with a thorough patient history and physical ...
Hepatitis B is one of the most widespread viral infections in the world, with hundreds of millions of people living with it today. Caused by the hepatitis B virus (HBV), this condition primarily ...
What Is Metabolic Dysfunction-Associated Steatohepatitis? Metabolic dysfunction-associated steatohepatitis, or MASH, is a form of liver disease. MASH occurs when fat accumulates in liver cells. Plenty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results